Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Article full text The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2021.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: on behalf of, Adis journals, Mease, Philip J., Lertratanakul, Apinya, Papp, Kim A., Bosch, Filip E. van den, Tsuji, Shigeyoshi, Dokoupilova, Eva, Keiserman, Mauro W., Bu, Xianwei, Chen, Liang, McCaskill, Reva M., Zueger, Patrick, McDearmon-Blondell, Erin L., Pangan, Aileen L., Tillett, William
Format: Video
Sprache:eng
Schlagworte:
Medicine
Rheumatology and Arthritis
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Article full text The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2021.
DOI:10.6084/m9.figshare.14216975